Clinical Trials Logo

Clinical Trial Summary

In ear, nose, throat (ENT) and jaw surgery departments, up to 60% of patients suffer from alcohol dependence (Allen et al., 2009), and may develop an alcohol withdrawal syndrome (AWS) when undergoing sur-gery. Caring for these patients creates a major challenge for all persons involved: Health care staff is not only challenged by the primary illness but also by increased risk of life-threatening complications (infection, bleeding, cardiopulmonary dysfunction, impaired wound healing, re-operation), higher mortality rate, and longer duration of hospitalization due to preoperative alcohol use and the development of an AWS (Delgado-Rodriguez, Gomez-Ortega, Mariscal-Ortiz, Palma-Perez, & Sillero-Arenas, 2003; Eyer et al., 2011; Foy, Kay, & Taylor, 1997; Genther & Gourin, 2012; Kuo et al., 2008; Mayo-Smith et al., 2004; McCusker, Cole, Abrahamowicz, Primeau, & Belzile, 2002; Neyman, Gourin, & Terris, 2005; O'Brien et al., 2007). Moreover, nearly five percent of all patients with an AWS develop an alcohol withdrawal delirium (AWD) which, without any therapy, will end lethally in 15% of all cases. With adequate medical and other interventions lethality is about two percent (Diener, 2003; Wright, Myrick, Henderson, Peters, & Malcolm, 2006). Additionally, the occurrence of an AWS and / or AWD represents a threatening, time-intensive and complex situation for family members (Repper-DeLisi et al., 2008; Yu et al., 2012).

Since 2011, in addition to patients undergoing short-term surgery, also patients with oncological diagnoses are hospitalized in the ENT and Jaw Surgery Department at the University Hospital Basel (USB). These patients are in need of prolonged surgical treatments and resulting longer periods of abstinence from food and drink, including alcohol and other substances, increase the risk of alcohol withdrawal. For instance, in the ENT and Jaw Surgery Department, in 2011, 74 out of 910 inpatients were at risk for or already experienced an AWD and 47 of them needed permanent supervision to guarantee their safety. Bridging the period of abstinence by drinking alcohol pre- and postoperatively is a suboptimal option for these patients due to the relatively long surgical treatment. This situation called for action: based on positive experiences within the dementia-delirium-programme of USB (Hasemann & Pretto, 2006), an evidence-based approach to screen for, detect and treat AWS and / or AWD in ENT and jaw surgery patients was developed and implemented (Hasemann, 2013). Now, this new approach needs to be evaluated.


Clinical Trial Description

The aims of the proposed study are to describe patient trajectories and to evaluate the processes and structures of the nurse-led approach in the ENT and Jaw Surgery Department at USB. The following research questions were generated:

Aim 1): Who are the patients captured with the algorithm, what are their risk factors, and how are the patient trajectories in terms of decisions, development, start, duration and ending of AWS and / or AWD? Specific questions asked:

- Which are demographic and medical characteristics of patients?

- How many patients are at risk for AWD / AWS?

- Which decisions do patients make?

- What is the time of onset, duration and ending of AWS and / or AWD?

- Were additional resources used to guarantee safety of patients?

Aim 2): How is the prevention algorithm adhered to? Specific questions asked:

- How many patients were risk-assessed by a nurse at hospital admission?

- How many patients or those who should have been asked were eventually asked to agree to substitution therapy?

- How many patients at risk were assessed using the Clinical Institute Withdrawal Assessment (CIWA)-Ar?

- How many times was the delirium expert consultation service contacted due to reasons stated in algorithm? ;


Study Design

Time Perspective: Retrospective


Related Conditions & MeSH terms


NCT number NCT02782156
Study type Observational
Source University Hospital, Basel, Switzerland
Contact
Status Completed
Phase N/A
Start date November 2014
Completion date June 2016

See also
  Status Clinical Trial Phase
Completed NCT00114439 - Lithium Cannabis Withdrawal Study Phase 2
Completed NCT00980044 - Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal Phase 2/Phase 3
Completed NCT02643355 - Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED N/A
Recruiting NCT00792415 - Validation of a Pediatric-Specific Abstinence Syndrome Assessment Tool N/A
Completed NCT02431728 - The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program Phase 1/Phase 2
Completed NCT00695864 - Effect of Ondansetron for Withdrawal Symptoms N/A
Active, not recruiting NCT02951793 - Abuse and Addiction in ICU
Completed NCT02108626 - Electronic Cigarettes in Daily Dependent Smokers Phase 4
Recruiting NCT04917185 - EA for PAAS: A pRCT N/A
Completed NCT02801357 - Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction Phase 1
Completed NCT01362959 - Nicotine Replacement Therapy in the Intensive Care Unit Phase 4
Completed NCT00992979 - Therapeutic Massage to Manage Withdrawal Related Anxiety Phase 2
Completed NCT02825459 - Does Abstinence From E-cigarettes Produce Withdrawal Symptoms? N/A
Completed NCT00900900 - The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers Phase 2
Completed NCT02318290 - Opioids Withdrawal Syndrome in Critically Ill Patients: a Multicenter Prospective Cohort Study N/A
Completed NCT00032968 - Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1 Phase 3
Completed NCT03374722 - Opioid Withdrawal Symptoms in Critically Ill Patients
Completed NCT03435614 - Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults
Completed NCT00570219 - The Effect of Valproate on Benzodiazepine Withdrawal Severity N/A
Completed NCT00367874 - Treatment of Polydrug-Using Opiate Dependents During Withdrawal Phase 4